Objective Atopic dermatitis (AD) is a chronic inflammatory skin disease that is complicated
by an increased risk for skin and systemic infections. Preventive therapy for AD is based on …

Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infections, which
cause significant morbidity and, if untreated, may become systemic. Staphylococcus aureus …

Background Current systemic treatments for children younger than 6 years with moderate-to-
severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal …

Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis
is made using evaluated clinical criteria. Disease activity and burden are best measured …

Background Children with severe atopic dermatitis (AD) have limited treatment options.
Objective We report the efficacy and safety of dupilumab+ topical corticosteroids (TCS) in …

Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD);
clarity about drug class safety considerations in the context of AD is important. Baricitinib, an …

Importance The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled,
moderate to severe atopic dermatitis (AD). Objective To assess the efficacy and safety of …

Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a
challenge. Authorities and physicians are still learning how COVID-19 affects people with …

With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Background Dupilumab [a monoclonal antibody blocking the shared receptor subunit for
interleukin (IL)‐4 and IL‐13] is approved for patients aged≥ 12 years with inadequately …